TITLE

Ruxolitinib

PUB. DATE
February 2016
SOURCE
Reactions Weekly;2/13/2016, Vol. 1588 Issue 1, p234
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents a case study of a 69 year old woman who was treated with ruxolitinib for myelofibrosis and had developed thrombocytopenia and cryptococcal meningoencephalitis as drug side effect.
ACCESSION #
112964760

 

Related Articles

  • Pipobroman.  // Reactions Weekly;11/1/2008, Issue 1226, p22 

    The article describes the case of a 55-year-old patient who developed during treatment with pipobroman for myelofibrosis. The patient had a three-month history of progressive nodule formation on the face. After being diagnosed with bromoderma, pipobroman was discontinued. The patient was treated...

  • Imatinib.  // Reactions Weekly;5/12/2007, Issue 1151, p17 

    The article presents a case study of a 55-year-old man with Philadelphia chromosome positive chronic myeloid leukaemia who developed myelofibrosis and proliferation of a JAK2V617F mutation during treatment with imatinib. The patient's blood parameters normalized within 11 months of imatinib...

  • Ruxolitinib.  // Reactions Weekly;Apr2015, Vol. 1546 Issue 1, p180 

    The article presents case reports of two patients with chronic kidney disease who experienced decreased haemoglobin and platelet counts while receiving ruxolitinib for myelofibrosis.

  • Study Links ESAs To Higher Leukemia Risk For Some. Young, Donna // BioWorld Today;12/12/2007, Vol. 18 Issue 240, p1 

    The article reports on a study that links erythropoiesis-stimulating agents (ESA), such as Aranesp, Epogen and Procrit, to higher leukemia risk for patients with a certain bone marrow disorder. In a study of 311 patients with myelofibrosis, researchers at the Mayo Clinic in Rochester, Minnesota,...

  • Peginterferon-α-2a.  // Reactions Weekly;Oct2014, Vol. 1523 Issue 1, p148 

    An abstract of the article "Reversible bone marrow aplasia induced by pegylated interferon-alpha-2a therapy in a patient with primary myelofibrosis," by N. R. Mainali and colleagues is presented.

  • Ruxolitinib.  // Reactions Weekly;Mar2015, Vol. 1541 Issue 1, p226 

    An abstract of the article "Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge," by F. Palandri and colleagues is presented.

  • Lenalidomide.  // Reactions Weekly;2/3/2007, Issue 1137, p18 

    The article presents a case study of a 73-year-old man who developed multiple splenic infarcts during treatment with lenalidomide. The patient received lenalidomide after diagnosis of myelofibrosis with dysplastic features. The man was later admitted with pneumonia and bronchospasm and received...

  • Romiplostim.  // Reactions Weekly;Jun2015, Vol. 1554 Issue 1, p159 

    An abstract of the article "Progression of romiplostim myelofibrosis to myeloproliferative neoplasm," by T. Dadfarnia and colleagues is presented.

  • Ruxolitinib.  // Reactions Weekly;2/13/2016, Vol. 1588 Issue 1, p233 

    The article presents two case studies of a 71 year old and a 64 year old women who had developed epistaxis during the treatment with rutolitinib and also informs that they both had a history of myelofibrosis.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics